Biolex to Present Final Phase 2b Results at EASL for Locteron(R) Next-Generation Controlled-Release Interferon for HCV
Biolex Therapeutics announced that final results from its Phase 2b trial of Locteron have been accepted for two presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL).... [more]
